Transarterial injection of H101 in combination with chemoembolization overcomes recurrent hepatocellular carcinoma

Abstract

Transcatheter arterial chemoembolization (TACE) has become the standard treatment modality for unresectable hepatocellular carcinoma (HCC). Nonetheless, the clinical outcomes in patients with unresectable HCC are often unsatisfactory, especially in those with recurrent HCC. H101, an E1B gene deleted adenovirus, is known to have a significant antitumor activity. In addition, local injection of H101 can enhance the effect of antitumor therapies (chemotherapy and radiotherapy). Transarterial H101 gene injection in combination with TACE may help to control refractory and recurrent HCC. In this study, we report a 55-year-old patient with recurrent HCC which was treated with transarterial injection of H101 in combination with TACE, leading to a good clinical prognosis of the patient.

Keywords: H101; Hepatocellular carcinoma; Therapy; Transcatheter arterial chemoembolization.

Figures

Figure 1

Magnetic resonance imaging. A: A hypodense nodule and hepatocellular carcinoma before therapy; B: A hypodense nodule with partial contrast enhancement before hepatectomy.

Figure 2

Contrast magnetic resonance imaging. A: A hypodense nodule with circle contrast manifestation after hepatectomy and the seventh Transcatheter arterial chemoembolization; B: Contrast computed tomography showing homogeneous dense retention of lipiodol within the entire tumor mass two months after treatment; C: Contrast computed tomography no recurrent mass 4 mo after treatment.

Figure 3

Changes in α-fetoprotein levels during and after treatment.